Trevi Therapeutics to Present Haduvio Data at September Conferences
Trevi Therapeutics said senior management will take part in virtual and in-person fireside chats in September. In Haduvio clinical trials, the oral nalbuphine ER therapy showed a statistically significant reduction in cough frequency and improved patient-reported outcomes in IPF-related chronic cough and in RCC, addressing major unmet need in conditions with no FDA-approved therapies.